Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEXATE-AQ PRESERVED vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), leading to depletion of tetrahydrofolate and inhibition of DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine synthesis and modulation of cytokine release.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
FDA-approved for acute lymphoblastic leukemia (ALL), meningeal leukemia, non-Hodgkin's lymphoma, mycosis fungoides, psoriatic arthritis, severe psoriasis, breast cancer, head and neck cancers, and rheumatoid arthritis. Off-label uses include ectopic pregnancy, inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, and lupus nephritis.
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
MEXATE-AQ PRESERVED (methotrexate) is administered intramuscularly, intravenously, or subcutaneously. For neoplastic diseases, typical adult doses range from 25-100 mg/m² weekly or 5-25 mg/m² every 6-12 hours for 2-6 doses. For rheumatoid arthritis, 7.5-20 mg once weekly. For psoriasis, 10-25 mg once weekly.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life is 3-10 hours for low-dose therapy; at high doses, half-life increases to 8-15 hours due to saturation of renal clearance. Clinical context: Prolonged half-life in renal impairment or third-space fluid accumulation.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Primarily metabolized hepatically to polyglutamated methotrexate (active form) via folylpolyglutamate synthetase; also undergoes oxidation via aldehyde oxidase. Excretion is primarily renal via glomerular filtration and active tubular secretion.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily renal (80-90% unchanged via glomerular filtration and active tubular secretion), with approximately 5-10% eliminated via biliary/fecal excretion. Enterohepatic recirculation occurs.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Approximately 50-60% bound to albumin, with binding saturable at high concentrations.
Approximately 20–30% bound to plasma proteins.
Vd is 0.4-0.8 L/kg, indicating distribution into total body water. Higher Vd (1-2 L/kg) in high-dose therapy due to tissue binding and polyglutamation.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Oral: 30-90% (dose-dependent, saturable absorption; lower at high doses). IM/Sub Q: 100% (complete absorption). IV: 100%.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
Contraindicated if creatinine clearance (Cr Cl) <10 m L/min. For Cr Cl 10-30 m L/min: reduce dose by 50%. For Cr Cl 30-60 m L/min: reduce dose by 25%. For Cr Cl >60 m L/min: no adjustment needed. Monitor renal function closely; high methotrexate doses may require additional hydration and alkalinization.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Contraindicated in Child-Pugh class C. For Child-Pugh class B: reduce dose by 50%. For Child-Pugh class A: no dose adjustment. Avoid use in patients with significant liver disease or chronic hepatitis. Monitor liver enzymes.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
For acute lymphoblastic leukemia: induction doses of 3.3-5 mg/m² IV or IM, or higher doses per protocol (e.g., 100-1000 mg/m² IV). For juvenile idiopathic arthritis: 10-15 mg/m² once weekly (max 20-25 mg). Doses based on body surface area; adjust for renal function.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
Elderly patients may have reduced renal function; start at low end of dose range (e.g., 5-7.5 mg weekly for rheumatoid arthritis). Monitor Cr Cl, liver function, and blood counts. Increased risk of myelosuppression and hepatotoxicity. Avoid high-dose methotrexate unless renal function confirmed adequate.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
Methotrexate can cause severe toxicity including myelosuppression, hepatotoxicity, nephrotoxicity, pulmonary fibrosis, and severe enterocolitis. Accidental overdose has led to fatalities. It should only be prescribed by physicians experienced with antimetabolite therapy and familiar with its toxicities.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Monitor for bone marrow suppression, hepatotoxicity (liver function tests), renal impairment (serum creatinine), pulmonary toxicity (pneumonia-like symptoms), gastrointestinal toxicity, neurotoxicity (especially in high-dose regimens), and increased risk of infections. Avoid concomitant NSAIDs with high-dose methotrexate. Use with caution in patients with ascites, pleural effusions, or dehydration.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Absolute: hypersensitivity to methotrexate; severe hepatic impairment; severe renal impairment (Cr Cl < 30 m L/min); severe bone marrow suppression; active infection; alcohol use disorder; pregnancy (Category X); breastfeeding. Relative: peptic ulcer disease; ulcerative colitis; obesity; diabetes.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
Avoid folic acid supplements unless prescribed by your doctor for toxicity management. Caffeine may decrease methotrexate efficacy; limit intake. No specific food restrictions other than maintaining adequate hydration. Avoid grapefruit juice as it may alter methotrexate metabolism.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Category X. First trimester: high risk of miscarriage, CNS and skeletal malformations. Second/third trimester: growth restriction, developmental delay.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
Contraindicated. Excreted in breast milk; M/P ratio unknown. Potential for infant toxicity.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
Increased clearance in pregnancy may require dose escalation; however, contraindicated in pregnancy.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
MEXATE-AQ PRESERVED (methotrexate) is a folate analog antimetabolite. Always verify dosing route: intrathecal use requires preservative-free formulation. Ensure adequate hydration and urine alkalinization (target urine p H >7.0) to prevent methotrexate precipitation in renal tubules. Monitor CBC, LFTs, and creatinine before each dose. Leucovorin rescue is mandatory for high-dose regimens; start 24 hours after methotrexate infusion and continue until methotrexate level <0.1 µmol/L. Avoid concomitant NSAIDs and sulfonamides methotrexate toxicity.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Take methotrexate exactly as prescribed; do not change dose or frequency without consulting your doctor.,Avoid alcohol completely due to increased risk of liver damage.,Drink plenty of fluids (at least 2-3 liters per day) to prevent kidney damage.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, mouth ulcers, cough, or shortness of breath immediately.,Use effective contraception during treatment and for at least 3 months after stopping (men and women).,Do not take NSAIDs (e.g., ibuprofen, naproxen) without your doctor's approval; they can increase methotrexate toxicity.,Avoid live vaccines while on treatment.,Store at room temperature, protect from light, and do not freeze.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEXATE-AQ PRESERVED vs CLADRIBINE, answered by our medical review team.
MEXATE-AQ PRESERVED is a Antineoplastic Agent that works by Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), leading to depletion of tetrahydrofolate and inhibition of DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine synthesis and modulation of cytokine release.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEXATE-AQ PRESERVED and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEXATE-AQ PRESERVED is: MEXATE-AQ PRESERVED (methotrexate) is administered intramuscularly, intravenously, or subcutaneously. For neoplastic diseases, typical adult doses range from 25-100 mg/m² weekly or 5-25 mg/m² every 6-12 hours for 2-6 doses. For rheumatoid arthritis, 7.5-20 mg once weekly. For psoriasis, 10-25 mg once weekly.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEXATE-AQ PRESERVED and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEXATE-AQ PRESERVED is classified as Category C. Category X. First trimester: high risk of miscarriage, CNS and skeletal malformations. Second/third trimester: growth restriction, developmental delay.. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.